fb-pixel Skip to main content
Dyno Therapeutics chief executive Eric Kelsic.

Dyno raises $100 million to bring artificial intelligence to gene therapy

Cambridge-based Dyno remained in stealth mode until March 2020, then quickly made a splashy debut, inking deals with Novartis, Sarepta, and Roche.

Moderna reports first profit, says early data show vaccine is 96 percent effective in adolescents

While Moderna recorded its first-ever profitable quarter, revenues of $1.94 billion came in below Wall Street expectations.

Drug pricing watchdog says there’s ‘insufficient’ evidence that Biogen’s Alzheimer’s medicine would help patients

In a draft report, Boston-based ICER cites conflicting data from two trials. The Cambridge biotech says it “does not accurately reflect the possible holistic value” of the experimental treatment.

Moderna booster shots show encouraging results against variants

The Cambridge biotech releases early study data showing the vaccine’s effect on antibody levels.

President Biden speaking about COVID-19 vaccinations last month.
Biden administration backs waiver of intellectual property protections for COVID-19 vaccines
The Biden administration is throwing its support behind efforts to waive intellectual property protections for COVID-19 vaccines in an attempt to speed the end of the pandemic.

An electronic billboard along Route 128 in Norwood advertises open jobs at Moderna.
Moderna will double Norwood plant’s size, says Mass. workforce has grown to 1,400
The expansion comes as Moderna rapidly adds to its workforce in Massachusetts. A spokesperson said the company has about 1,400 full-time employees here,

Latest Headlines in Biotech

A man walks by Pfizer headquarters in New York.

Pfizer posts $4.9 billion profit in the first quarter as vaccine strategy pays off

Once viewed as a marketing machine for blockbuster treatments such as Viagra and Lipitor, Pfizer has transformed itself into a powerhouse for delivering drugs that treat cancer, rare diseases — and vaccines.

Palestinian medics unpack Moderna COVID-19 vaccines and supplies that are designated for front-line medical workers.

Moderna to supply 500 million vaccine doses to WHO’s struggling Covax initiative

Moderna will supply a vaccination campaign backed by the World Health Organization with up to 500 million doses of its coronavirus vaccine starting late this year, a much-needed boost to a global initiative that has been plagued by stark inequity, funding shortfalls, and a severe supply crunch.

Luk Vandenberghe, scientific cofounder of Affinia Therapeutics and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, and Livia Carvalho.

Waltham biotech raises $110 million for gene therapy treatments

Affinia Therapeutics, founded in 2019, is working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear.

An aerial view of Kendall Square in Cambridge.

Another class of biotech companies are about to go public in Massachusetts

Massachusetts is about to see another class of young biotech firms take the next step and become public companies, with a flurry of filings in just the past few weeks.

Lauren Farley and her mother, Susan, march through Kendall Square on their way to Biogen during a rally on March 30 for their aunt and sister-in-law, Lisa Stockman Mauriello, who has been diagnosed with a rare and aggressive form of ALS. Her friends and supporters are beseeching Biogen to grant her compassionate use of a drug, tofersen, that could save her life.

Biogen to make experimental ALS drug available to dying patients

Biogen said it will make an experimental medicine for Lou Gehrig’s disease available to some people who are dying of the incurable illness starting in July, following months of pressure from patients who had no other treatment options.

Vials of the Moderna COVID-19 vaccine at the Recipharm plant in France.

Sanofi signs deal to help make Moderna’s COVID-19 vaccine in the US

The French pharmaceutical giant said Monday it will help manufacture up to 200 million doses of Cambridge-based Moderna’s vaccine at Sanofi’s plant in Ridgefield, N.J.

A sign at the Vertex Pharmaceuticals headquarters in the Seaport.

Vertex doubles down on gene editing in $900 million investment with CRISPR Therapeutics

The companies are working on a gene-editing therapy that could cure sickle cell disease and a similar inherited blood disorder known as beta thalassemia.

Tillman Gerngross is cofounder and chief executive of Adagio Therapeutics.

Adagio raises $336 million to advance COVID-19 antibody treatment

Last week, the Waltham biotech began recruitment for a global clinical trial to test the drug’s efficacy as a treatment for high-risk individuals with mild or moderate COVID-19.